Savara (SVRA) Net Income towards Common Stockholders (2010 - 2026)
Savara's (SVRA) quarterly Net Income towards Common Stockholders came in at -$37.3 million in Q1 2026, down 39.96% year-on-year from -$62.1 million in Q1 2025, and down 15.66% on a QoQ basis from -$32.2 million in Q4 2025.
Savara (SVRA) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$37.3 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 39.96% year-over-year to -$37.3 million in Q1 2026; TTM through Mar 2026 was -$129.5 million, a 26.73% decrease from a year earlier, with the FY2025 full-year figure at -$118.8 million, down 23.94% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$37.3 million, down from -$32.2 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for SVRA reached as high as -$8.3 million in Q1 2022 and fell as low as -$37.3 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$20.3 million across 5 years, with a median of -$20.3 million in 2024.
- Across the five-year window, Net Income towards Common Stockholders rose 18.76% in 2022 and tumbled 94.38% in 2024, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$10.3 million in 2022, then tumbled by 56.3% to -$16.1 million in 2023, then slumped by 80.41% to -$29.0 million in 2024, then declined by 10.99% to -$32.2 million in 2025, then dropped by 15.66% to -$37.3 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$37.3 million in Q1 2026, -$32.2 million in Q4 2025, and -$29.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | -37.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.28 Mn |
| Dec 31, 2025 | -32.24 Mn |
| Sep 30, 2025 | -29.56 Mn |
| Jun 30, 2025 | -30.40 Mn |
| Mar 31, 2025 | -26.64 Mn |
| Dec 31, 2024 | -29.04 Mn |
| Sep 30, 2024 | -24.25 Mn |
| Jun 30, 2024 | -22.24 Mn |
| Mar 31, 2024 | -20.35 Mn |
| Dec 31, 2023 | -16.10 Mn |
| Sep 30, 2023 | -16.60 Mn |
| Jun 30, 2023 | -11.44 Mn |
| Mar 31, 2023 | -10.56 Mn |
| Dec 31, 2022 | -10.30 Mn |
| Sep 30, 2022 | -10.39 Mn |
| Jun 30, 2022 | -9.16 Mn |
| Mar 31, 2022 | -8.30 Mn |
| Dec 31, 2021 | -11.31 Mn |
| Sep 30, 2021 | -10.55 Mn |
| Jun 30, 2021 | -10.94 Mn |